Want to join the conversation?
Biopharmaceutical company $GILD said that its Marketing Authorization Application (MAA) for tenofovir alafenamide (TAF) 25mg has been fully validated and is under assessment by the European Medicines Agency (EMA). This drug is an investigational, once-daily treatment for adults with chronic hepatitis B virus infection, an inflammation of the liver.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.